Supernus Pharmaceuticals, INC Form 4 insider transactions

Supernus Pharmaceuticals CEO Jack Khattar exercised stock options and sold a portion of the acquired shares under a pre-arranged trading plan.

Jack A. Khattar, CEO of Supernus Pharmaceuticals, reports a transfer of 16,850 shares from the KBT Trust to direct ownership on April 2, 2025.

CEO Jack A. Khattar settles performance share units, resulting in adjustments to his direct and indirect holdings of Supernus Pharmaceuticals stock.

Timothy Dec, Senior Vice President & CFO of Supernus Pharmaceuticals, reports the acquisition and disposal of common stock related to performance share unit settlements.

CEO Jack A. Khattar settled performance share units and had shares withheld for tax obligations, according to a recent SEC filing.

Frank Mottola, SVP at Supernus Pharmaceuticals, settled performance share units and sold shares to cover tax obligations on March 7, 2025.

Frank Mottola, SVP at Supernus Pharmaceuticals, disposed of shares to cover tax withholding requirements related to vesting Restricted Stock Units.

Jonathan Rubin, SVP and Chief Medical Officer of Supernus Pharmaceuticals, reported the disposal of common stock to cover tax withholding requirements related to vesting Restricted Stock Units.

Timothy Dec, CFO of Supernus Pharmaceuticals, reported the disposal of common stock to cover tax withholding obligations related to vesting Restricted Stock Units.

Padmanabh P. Bhatt, Sr. VP of IP and CSO at Supernus Pharmaceuticals, disposed of shares to cover tax withholding requirements related to vesting Restricted Stock Units.

Jack Khattar, CEO of Supernus Pharmaceuticals, reports acquisition of performance share units and adjustments to his beneficial ownership of company stock.

Timothy Dec, Senior Vice President & CFO of Supernus Pharmaceuticals, reports the acquisition of performance share units.

Frank Mottola, SVP at Supernus Pharmaceuticals, reports the exercise and disposal of performance share units to cover tax obligations.

Padmanabh P. Bhatt, Sr. VP of IP and CSO at Supernus Pharmaceuticals, reports transactions involving common stock and derivative securities, including the vesting and settlement of performance share units and restricted stock units.

Jonathan Rubin, SVP, Chief Medical Officer of Supernus Pharmaceuticals, reports the acquisition and disposal of common stock and derivative securities, including performance share units and restricted stock units.

Frank Mottola, SVP at Supernus Pharmaceuticals, reports acquisition and disposal of common stock and derivative securities.

Timothy C. Dec, Senior Vice President & CFO of Supernus Pharmaceuticals, reports the acquisition and disposal of common stock and restricted stock units.

Director Frederick M. Hudson acquired 5,369 shares of Supernus Pharmaceuticals common stock through the vesting of restricted stock units on February 22, 2025.

Director Charles W. Newhall III reports the settlement of restricted stock units into Supernus Pharmaceuticals common stock.

Director Georges Gemayel reports acquisition and disposal of Supernus Pharmaceuticals common stock and restricted stock units on February 22, 2025.

Director Carrolee Barlow of Supernus Pharmaceuticals reports the acquisition and disposal of common stock and restricted stock units on February 22, 2025.

Director Bethany Sensenig reports acquisition of 5,369 shares of Supernus Pharmaceuticals common stock through the vesting of restricted stock units.

Frank Mottola, SVP at Supernus Pharmaceuticals, reports acquisition of stock options and restricted stock units.

Director Frederick M. Hudson reports acquisition of stock options and restricted stock units in Supernus Pharmaceuticals.

Director Charles W. Newhall III receives stock options and restricted stock units from Supernus Pharmaceuticals.

Director Georges Gemayel acquired stock options and restricted stock units in Supernus Pharmaceuticals on February 19, 2025.

Director Bethany Sensenig reports acquisition of stock options and restricted stock units in Supernus Pharmaceuticals.

Director Carrolee Barlow acquired stock options and restricted stock units in Supernus Pharmaceuticals on February 19, 2025.

Padmanabh P. Bhatt, a Senior VP at Supernus Pharmaceuticals, received stock options and restricted stock units on February 19, 2025.

Jonathan Rubin, SVP, Chief Medical Officer of Supernus Pharmaceuticals, reports the acquisition of stock options and restricted stock units.